You are here: Industry Insights > muscular dystrophy

News List

Casma Therapeutics raises $50m to support muscular dystrophy pharmaceutical-technology
September 14, 2020
US-based biotechnology company Casma Therapeutics has secured $50m in a Series B financing round to support the development of a programme targeting muscular dystrophy treatment.
Pfizer terminates domagrozumab (PF-06252616) clinical studies for the treatment of Duchenne muscular dystrophy worldpharmanews
September 06, 2018
Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD): a Phase 2 safety and efficacy study (B5161002) and an open-label extension
Gene 'Editing' in Dog Study Shows Promise for Kids With Muscular Dystrophy drugs
August 31, 2018
For the first time, scientists report using gene-editing technology to halt the progression of muscular dystrophy in dogs -- suggesting a possible breakthrough for children with a form of the disease.
Sarepta adds muscular dystrophy gene therapies via Myonexus pact fiercebiotech
May 07, 2018
Sarepta is determined to stay at the forefront of genetic medicines for muscular dystrophies and to that end has signed another R&D deal—this time with Myonexus Therapeutics—and taken an option on buying the company.
Tamoxifen and raloxifene slow down the progression of muscular dystrophy europeanpharmaceuticalreview
March 22, 2018
Long-term treatment with selective estrogen receptor modulators improves muscle, respiratory, and skeletal function without weakening bone in new mouse studies…